Answers are grounded in this paper and cite their sources.
A facile, sensitive, and label-free aptamer-based fluorescent biosensor (aptasensor) for chloramphenicol (CAP) detection was successfully developed based on an aggregation-induced emission (AIE) probe and graphene oxide (GO). In this aptasensor, the specific aptamer of CAP (C-Apt) is used as the recognition part, an AIE molecule, 9,10-distyrylanthracene (DSA) derivative with short alkyl chains (9,10-bis{4-[2-(N,N,N-trimethylammonium)-ethoxy]styrene}anthracene dibromide, DSAC2N), as the fluorescent probe, and GO with a low oxidation degree as the fluorescent quencher. Initially, the AIE probe DSAC2N and C-Apt could be adsorbed on GO through π-stacking interactions, and the fluorescence of DSAC2N could be efficiently quenched due to the energy transfer between DSAC2N and GO. When CAP is added, C-Apt can preferentially bind with CAP and the newly formed complex (C-Apt–CAP) can be released from GO, resulting in the recovery of the fluorescence signal of DSAC2N. Thus, with the aid of GO, turn-on detection of CAP can be readily realized by monitoring the fluorescence signal of DSAC2N from “off” to “on”. Under the optimized conditions, the aptasensor exhibits a high sensitivity toward CAP with a limit of detection of 1.26 pg/mL. Besides, we have successfully applied this aptasensor to the detection of CAP in spiked milk.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: